{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Balevic SJ"],"funding":["NCATS NIH HHS","NIAMS NIH HHS"],"pagination":["e247615"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11046337"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(4)"],"pubmed_abstract":["<h4>Importance</h4>The pharmacokinetics of abatacept and the association between abatacept exposure and outcomes in patients with severe COVID-19 are unknown.<h4>Objective</h4>To characterize abatacept pharmacokinetics, relate drug exposure with clinical outcomes, and evaluate the need for dosage adjustments.<h4>Design, setting, and participants</h4>This study is a secondary analysis of data from the ACTIV-1 (Accelerating COVID-19 Therapeutic Interventions and Vaccines) Immune Modulator (IM) randomized clinical trial conducted between October 16, 2020, and December 31, 2021. The trial included hospitalized adults who received abatacept in addition to standard of care for treatment of COVID-19 pneumonia. Data analysis was performed between September 2022 and February 2024.<h4>Exposure</h4>S"],"journal":["JAMA network open"],"pubmed_title":["Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial."],"pmcid":["PMC11046337"],"funding_grant_id":["UL1 TR003017","UL1 TR002544","UL1 TR002489","UL1 TR002345","UL1 TR002366","UL1 TR001453","UL1 TR002553","UL1 TR001881","UL1 TR001430","UL1 TR001998","U24 TR001579","UL1 TR002645","UL1 TR001445","UL1 TR003107","UL1 TR002319","U24 TR001608","K23 AR075874","UL1 TR003096"],"pubmed_authors":["Becerra Nunez CC","Bah F","Ditondo J","Patel A","Bakos K","Flanagan J","Russo G","Thapamager S","Patel B","Linas B","Williams D","Abba T","Gomez C","Crespo A","Sanyal A","Ayres C","Flint K","Holyfield I","Pille A","Rodeles L","Herrejon E","Patel S","Stadnik C","Schulz T","Patel M","Mello Roux Leite M","Tavadze M","Philogene K","Ponce PO","Salsgiver E","Roebuck M","Balani B","Borsetta E","Sebhatu R","Gonzalez D","Alonso JE","Mansilla M","Miller N","Castillo K","Hamilton H","Harrington C","Kelly S","Cao H","Donlinger S","Henry C","O'Rourke A","Choudhury N","Reece R","Klebert M","Betteta Riondato S","Dare R","Glassman S","Hinojosa E","Wong M","Jenkins M","Schodl N","Heard P","Plate M","Bowling JE","Green J","Castagne M","Gray K","Camilo Endo Carvajal M","Perez-Velazquez J","Murga G","Neyra S","Sabin A","Balevic SJ","Hornik CP","Barreda Sanchez C","Presti R","Robb K","Molina D","Rao S","Serrano RC","Alberdi L","Smith PB","Olson R","Falla Benites M","Eduarda Claus M","Dixon DO","Molina M","Toledo M","Goh S","Murray C","Hernandez J","Abdelghany M","Javeri H","Hill N","Rao M","Del Carpio F","Guala ME","Ravera L","Garcia V","Malca J","Serravalle P","Mompoint D","Nelson N","Arrington A","Gramagalia C","Soileau B","Higareda Almaraz I","Garcia A","Chandramohan D","Cristaldi ME","Parnia S","Lewis D","Di Renzo P","Fenes M","Juneja K","Devine M","Pierobon J","Spec A","Mardari G","Cenname M","Stevens M","O'Sullivan A","Lahitte M","Hermenegildo I","Afghanzada A","De Bona L","Morris P","Sands K","Gavin B","Bozzette S","Alba Ponce AM","Madrigal Robles VH","Lind B","Biondi R","Marathe J","Mendez S","Soule D","Bianchi C","Carbajal O","Calderon Galvez J","Goss C","Thompson R","Pinero G","Baldan S","Yaringano Palacios M","Stevens B","Rodarte Rodriguez MF","Carlson Marti E","Chacaltana G","Anderson C","Putta N","Breemo A","Yow E","Chaina J","Breslin M","Spitz T","Sanchez R","Tessini A","Castro M","Bello F","Matos M","Doshi P","Mohaddes S","Baxter J","Chaio S","Martin J","Sadeh J","Dentino A","Dodson S","ACTIV-1 IM Study Group","Ceriolli Breda F","Sandoval N","Broughal K","Beumont-Mauviel M","Engemann JJ","Nawwar A","Blamoun J","Christian Sanchez Carrillo H","Palacios K","Catano G","McCarthy MW","Ca H","Alleyne C","Gwak A","de la Cruz Barba NE","Cardozo Fernandes J","Dolz M","Pezzini S","Springer J","Tragus R","Kim H","Gadhia AD","Gamarra Velarde R","Shroba J","Alzogaray MF","Stock T","Erhardt W","Lee J","Kuek A","Benitez A","Scholler I","Jasion T","Quill CM","Torres P","Schroeder R","Calderon JM","Bharucha DB","McLendon-Arvik B","Burgos R","Lindsey B","Galarza Cuba D","de la Cruz C","Rosas Ismerio MF","Polo E","Mondino A","Miserere ME","Schneider B","Zuain M","Chiang A","Benzaquen N","Alyatim R","Kalaria D","Mason R","Mitchell J","Swartz M","Oscar Riera F","Gardner B","Small C","Leimberger J","Delgado Malaga S","Cox K","Toibaro JJ","Cabo A","Ramos J","Huang Z","Harris ES","Eisnor D","Karfonta B","Taylor BS","Ehwarieme R","Milbradt T","Lovelett C","Wessolossky M","Bengtson CD","Haile A","Brown G","Wu H","DeZure A","Dandachi D","Herald F","Zuloeta F","Spagnoletti J","Sallee K","Camacho A","Pic C","Olmos Meza NE","Powderly WG","Aouad A","Iyer V","Patterson JE","Co M","Morse CG","Ferini F","Elliott C","Portilla LM","Linas BP","Malamud N","Gave J","Icochea Perez ML","Beci R","Hubert S","Ceraldi G","Jara Y","Garg J","Sanchez Morales S","Sinha S","Pachioli V","Vehe K","Vepa S","Yang O","Plewa J","Mano A","Benjamin DK","Dorr P","Grant P","Schmid A","Middleton EA","Read S","Sogoian D","Lindsell CJ","Anjum J","Villegas-Chiroque M","Huvane J","Barajas RA","Cerbino Neto J","Brody B","Holter-Chakrabarty J","Losso MH","Williamson J","Kurilla M","Blair L","Smith A","Roundy T","Rutter J","Wahid L","Marshall G","Garcia-Diaz J","Pickell N","Nguyen J","Meisenberg B","Wortmann G","Whitt L","Jaremczuk D","Kessels L","Lovell K","Vazquez D","Varner K","de la Gala S","Echeverria S","Schmitt C","Shaw LK","Bojanowski CM"],"additional_accession":[]},"is_claimable":false,"name":"Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial.","description":"<h4>Importance</h4>The pharmacokinetics of abatacept and the association between abatacept exposure and outcomes in patients with severe COVID-19 are unknown.<h4>Objective</h4>To characterize abatacept pharmacokinetics, relate drug exposure with clinical outcomes, and evaluate the need for dosage adjustments.<h4>Design, setting, and participants</h4>This study is a secondary analysis of data from the ACTIV-1 (Accelerating COVID-19 Therapeutic Interventions and Vaccines) Immune Modulator (IM) randomized clinical trial conducted between October 16, 2020, and December 31, 2021. The trial included hospitalized adults who received abatacept in addition to standard of care for treatment of COVID-19 pneumonia. Data analysis was performed between September 2022 and February 2024.<h4>Exposure</h4>S","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-03T03:55:37.069Z","creation":"2026-04-24T03:09:35.585Z"},"accession":"S-EPMC11046337","cross_references":{"pubmed":["38662372"],"doi":["10.1001/jamanetworkopen.2024.7615"]}}